Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: mannitol; silicon dioxide; magnesium stearate; povidone; pregelatinised maize starch - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; mannitol; silicon dioxide; povidone - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; silicon dioxide; povidone; magnesium stearate; mannitol - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: silicon dioxide; povidone; magnesium stearate; mannitol; pregelatinised maize starch - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; silicon dioxide; mannitol; povidone - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; mannitol; magnesium stearate; povidone; silicon dioxide - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet, uncoated - excipient ingredients: silicon dioxide; pregelatinised maize starch; magnesium stearate; povidone; mannitol - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; magnesium stearate; silicon dioxide; povidone; mannitol - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; pregelatinised maize starch; povidone; mannitol - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.